Physician profile
Elena Eckard
NPI 1346684859
$3,896.26
in general payments reported to CMS, 2019-2025
27 companies · $617 in 2025
The $617 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $850 · 2022: $836 · 2023: $1,115 · 2024: $478 · 2025: $617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,210.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,089.86 | 2023-2025 | Minimed 780g, Intellis Adaptivestim |
| Novo Nordisk INC | $752.92 | 2021-2025 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $260.47 | 2021-2022 | |
| Lilly USA, LLC | $249.07 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $247.37 | 2022 | |
| Bigfoot Biomedical INC | $231.65 | 2022-2023 | Unity Diabetes Management System |
| Insulet Corporation | $145.64 | 2021 | |
| Ascensia Diabetes Care US INC. | $132.90 | 2022-2024 | |
| Ascendis Pharma Endocrinology INC | $114.48 | 2025 | Yorvipath |
| Abbott Laboratories | $109.57 | 2021-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $79.07 | 2023 | Korlym |
| Boston Scientific Corporation | $64.14 | 2023-2024 | Ranger |
| Tandem Diabetes Care, INC. | $46.34 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $42.41 | 2022-2024 | |
| Dexcom, INC. | $37.52 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $35.40 | 2023 | Gvoke Hypopen |
| Mannkind Corporation | $33.43 | 2022-2023 | Afrezza |
| Madrigal Pharmaceuticals | $32.58 | 2025 | Rezdiffra |
| Beta Bionics, INC. | $28.92 | 2023 | Ilet Bionic Pancreas |
| Abbvie INC. | $24.98 | 2021 | |
| Horizon Therapeutics Plc | $24.97 | 2021 | |
| Kyowa Kirin, INC. | $23.97 | 2025 | |
| Amryt Pharma Holdings LTD | $23.62 | 2023 | Myalept |
| Recordati_rare_diseases_inc. | $21.17 | 2021 | |
| Cequr Corporation | $15.00 | 2022 | |
| Currax Pharmaceuticals LLC | $14.83 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.98 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elena Eckard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.